Phase 3 SEAL study of selinexor (Xpovio) meets primary l in patients with unresectable dedifferentiated liposarcoma
RCT (n=285) showed treatment with this novel CRM1 nuclear export inhibitor, increased progression-free survival compared to placebo with a reduction in the risk of disease progression or death by approx 30% (hazard ratio 0.70; p=0.023).
Source:
Biospace Inc.
SPS commentary:
RCT (n=285) showed treatment with selinexor (Xpovio), a novel CRM1 nuclear export inhibitor, statistically significantly increased progression-free survival compared to placebo (hazard ratio=0.70; p=0.023) and reduced the risk of disease progression or death by approx. 30%.